Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 07/17 07:39:25 am
93.255 EUR   +0.09%
07/12Lanxess water treatment unit attracts interest - sources
RE
07/11BAYER : Still trending down
07/10BAYER : U.S. judge allows lawsuits over Monsanto's Roundup to procee..
RE
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Bayer : New Environmental and Molecular Mutagenesis Study Findings Have Been Reported by Researchers at Bayer (Classification of in vitro genotoxicants using...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:27pm CEST

New Environmental and Molecular Mutagenesis Study Findings Have Been Reported by Researchers at Bayer (Classification of in vitro genotoxicants using a novel multiplexed biomarker assay compared to the flow cytometric micronucleus test)

By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators publish new report on Environmental and Molecular Mutagenesis. According to news originating from Berlin, Germany, by NewsRx correspondents, research stated, "Regulatory in vitro genotoxicity testing exhibits shortcomings in specificity and mode of action (MoA) information. Thus, the aim of this work was to evaluate the performance of the novel MultiFlow assay composed of mechanistic biomarkers quantified in TK6 cells after treatment (4 and 24 hr): gH2AX (DNA double strand breaks), phosphorylated H3 (mitotic cells), translocated p53 (genotoxicity), and cleaved PARP1 (apoptosis)."

Our news journalists obtained a quote from the research from Bayer, "A reference dataset of 31 compounds with well-established MoA was studied using the MicroFlow micronucleus assay. A positive call was raised following the earlier published criteria from Litron Laboratories. In the light of our data, these evaluation criteria should probably be adjusted since only 8/11 (73%) nongenotoxicants and 18/20 (90%) genotoxicants were correctly identified. Moreover, there is a need for new in vitro tools to delineate the predominant MoA as in the MicroFlow assay only 5/9 (56%) aneugens and 4/11 (36%) clastogens were correctly classified. In contrast, the MultiFlow assay provides more in-depth information about the MoA and therefore reliably discriminates clastogens, aneugens, and nongenotoxicants. By using a lab-specific, practical threshold for the aforementioned biomarkers, 10/11 (91%) nongenotoxicants and 19/20 genotoxicants (95%), 9/11 (82%) clastogens, and 8/9 (89%) aneugens were correctly categorized, suggesting a clear improvement over the MicroFlow. Furthermore, the MultiFlow markers were benchmarked against established methods to assess the validity of the data. Altogether, these findings demonstrated good agreement between the MultiFlow assay and the benchmarking methods."

According to the news editors, the research concluded: "Finally, p21 may improve class discrimination given the correct identification of 4/4 (100%) aneugens and 2/5 (40%) clastogens."

For more information on this research see: Classification of in vitro genotoxicants using a novel multiplexed biomarker assay compared to the flow cytometric micronucleus test. Environmental and Molecular Mutagenesis, 2017;():. (Wiley-Blackwell - www.wiley.com/; Environmental and Molecular Mutagenesis - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1098-2280)

The news correspondents report that additional information may be obtained from S. Wilde, Investigational Toxicology, Bayer AG, Berlin, Germany. Additional authors for this research include M. Dambowsky, C. Hempt, A. Sutter and N. Queisser (see also Environmental and Molecular Mutagenesis).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1002/em.22130. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Berlin, Europe, Germany, Genetics, Environmental and Molecular Mutagenesis.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
07/12BAYER : Findings from Bayer in the Area of Medical Statistics Described (A Bayes..
AQ
07/12Lanxess water treatment unit attracts interest - sources
RE
07/10BAYER : U.S. judge allows lawsuits over Monsanto's Roundup to proceed to trial
RE
07/06BAYER : expands strategic alliance with Broad Institute of MIT and Harvard
AQ
07/06BAYER : Greenberg Traurig Advised Tecnoquimicas on Acquisition of MK Generics Bu..
AQ
07/05BAYER : Findings from Bayer Reveals New Findings on Personalized Medicine (Recen..
AQ
07/04Thyssenkrupp, Tata Steel may need asset sales to get EU nod for JV
RE
07/04BAYER : Animal Health and Mitsui Chemicals Agro sign global license agreement
PU
07/03Bayer sees Brazil as key growth driver for global crop division
RE
06/30BAYER : Broad and Bayer Expand Partnership, Launching New Research Effort to Dev..
AQ
More news
News from SeekingAlpha
07/123 THINGS IN BIOTECH, JULY 12 : Immunotherapy Brawl, And A Creeper In The Weeds 
07/10Judge says lawsuits alleging Roundup weedkiller causes cancer can go to trial 
07/05Bayer Animal Health in-licenses IP from Mitsui Chemicals Agro for parasiticid.. 
07/03YOUR DAILY PHARMA SCOOP : Redhill's New Patent, Nuvectra Slips, Teligent Gains 
07/03U.S. CORPORATE BOND MARKET BRACES FO : Bloomberg 
Financials (€)
Sales 2018 39 181 M
EBIT 2018 7 781 M
Net income 2018 4 973 M
Debt 2018 33 285 M
Yield 2018 2,99%
P/E ratio 2018 18,84
P/E ratio 2019 16,75
EV / Sales 2018 3,07x
EV / Sales 2019 2,55x
Capitalization 87 091 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 116 €
Spread / Average Target 24%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER-8.97%101 760
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
NOVARTIS-4.54%201 464
ROCHE HOLDING LTD.-5.78%200 973
MERCK AND COMPANY11.23%169 193